Picton Mahoney Asset Management Buys 7,750 Shares of Glaukos Corp (NYSE:GKOS)

Picton Mahoney Asset Management increased its stake in Glaukos Corp (NYSE:GKOS) by 18.8% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 49,050 shares of the medical instruments supplier’s stock after acquiring an additional 7,750 shares during the period. Picton Mahoney Asset Management’s holdings in Glaukos were worth $3,699,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of GKOS. C WorldWide Group Holding A S grew its holdings in Glaukos by 372.8% during the 2nd quarter. C WorldWide Group Holding A S now owns 209,265 shares of the medical instruments supplier’s stock worth $15,779,000 after acquiring an additional 165,000 shares during the period. Amundi Pioneer Asset Management Inc. grew its holdings in Glaukos by 136.7% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 178,502 shares of the medical instruments supplier’s stock worth $13,989,000 after acquiring an additional 103,102 shares during the period. State of Wisconsin Investment Board grew its holdings in Glaukos by 29.7% during the 1st quarter. State of Wisconsin Investment Board now owns 222,400 shares of the medical instruments supplier’s stock worth $17,429,000 after acquiring an additional 50,900 shares during the period. Norges Bank acquired a new stake in Glaukos during the 4th quarter worth $2,803,000. Finally, Geode Capital Management LLC grew its holdings in Glaukos by 14.0% during the 4th quarter. Geode Capital Management LLC now owns 365,226 shares of the medical instruments supplier’s stock worth $20,513,000 after acquiring an additional 44,867 shares during the period. Hedge funds and other institutional investors own 99.92% of the company’s stock.

In other news, CFO Joseph E. Gilliam sold 2,500 shares of the business’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $73.25, for a total value of $183,125.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 21,596 shares of company stock valued at $1,612,742 in the last three months. 8.70% of the stock is owned by company insiders.

A number of analysts have commented on the stock. BTIG Research reaffirmed a “hold” rating on shares of Glaukos in a report on Sunday, August 11th. Zacks Investment Research raised shares of Glaukos from a “hold” rating to a “strong-buy” rating and set a $82.00 target price for the company in a report on Tuesday, April 30th. Finally, BMO Capital Markets lifted their target price on shares of Glaukos from $66.00 to $71.00 and gave the stock a “market perform” rating in a report on Thursday, May 9th. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $72.56.

Shares of GKOS stock traded down $2.58 on Friday, hitting $58.58. The stock had a trading volume of 312,940 shares, compared to its average volume of 660,425. Glaukos Corp has a twelve month low of $42.17 and a twelve month high of $84.65. The firm has a market cap of $2.23 billion, a P/E ratio of -158.32 and a beta of 1.61. The company has a current ratio of 6.49, a quick ratio of 6.04 and a debt-to-equity ratio of 0.43. The company has a fifty day moving average price of $72.42 and a two-hundred day moving average price of $71.82.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.03). Glaukos had a negative net margin of 5.93% and a negative return on equity of 5.77%. The firm had revenue of $58.60 million during the quarter, compared to analyst estimates of $56.24 million. During the same period last year, the firm earned ($0.15) EPS. Glaukos’s quarterly revenue was up 35.8% on a year-over-year basis. On average, analysts expect that Glaukos Corp will post -0.39 earnings per share for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.

Further Reading: The Discount Rate – What You Need to Know

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corp (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.